The pharmacologic treatment of arrhythmias has seen little advance over the past few years. Physicians treating life threatening or hemodynamically destabilizing arrhythmias depend almost entirely on intravenous (IV) amiodarone. This is regrettable due to the multiple toxicities of amiodarone and its long half-life. Once administered, it is a therapeutic commitment to long-term therapy. Given the very long terminal elimination half-life, treatment with amiodarone may interfere with baseline electrophysiologic studies and ablation procedures. Additionally, the side effect profile can be consequential, even with brief periods of treatment. Currently, sotalol, like amiodarone, is available in both IV and oral formulations, facilitating their use in emergency situations. IV sotalol has a rapid onset of action with linear pharmacokinetics. While sotalol’s efficacy has mostly been evaluated in small clinical trials, 2 recent meta-analysis have been informative as to the utility of sotalol. Sotalol has similar efficacy as amiodarone, but has much more favorable adverse event profile. IV sotalol has been underutilized and could offer advantage in the treatment of AF for rate and rhythm control, as well in the pediatrics for treatment of supraventricular arrhythmias often resistant to other therapies.

Keywords:
Intravenous sotalol, Arrhythmia, Antiarrhythmic agents, Treatment, Commentary
1.
Antonaccio MJ, Gomoll A: Pharmacology, pharmacodynamics and pharmacokinetics of sotalol. Am J Cardiol 1990; 65: 12A–21A.
2.
Hara T: Cardiovascular drugs; in Petrova E (ed): Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development. Northampton, Elgar Publishing, 2003, pp 38–61.
3.
Anderson JL, Prystowsky EN: Sotalol: an important new antiarrhythmic. Am Heart J 1999; 137: 388–409.
4.
Anderson JL, Askins JC, Gilbert EM, Miller RH, Keefe DL, Somberg JC, Freedman RA, Haft LR, Mason JW, Lessem JN: Multicenter trial of sotalol for suppression of frequent, complex ventricular arrhythmias: a double-blind, randomized, placebo-controlled evaluation of two doses. J Am Coll Cardiol 1986; 8: 752–762.
5.
Somberg JC, Preston RA, Ranade V, Molnar J: QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol. Cardiology 2010; 116: 219–225.
6.
Somberg JC, Preston RA, Ranade V, Molnar J: Developing a safe intravenous sotalol dosing regimen. Am J Ther 2010; 17: 365–372.
7.
Ho DSW, Zecchin RP, Cooper MJ, Richards DAB, Uther JB, Ross DL: Rapid intravenous infusion of d-1 sotalol: time to onset of effects on ventricular refractoriness, and safety. Eur Heart J 1995; 16: 81–86.
8.
Kerin NZ, Jacob S: The efficacy of sotalol in preventing postoperative atrial fibrillation: a meta-analysis. Am J Med 2011; 124: 875.e1–e9.
9.
Milan DJ, Saul JP, Somberg MC, Molnar J: Efficacy of intravenous and oral sotalol in pharmacologic conversion of atrial fibrillation: a systematic review and meta-analysis. Cardiology 2017: 136: 52–60.
10.
Marill KA, Runge T: Meta-analysis of the risk of torsades de pointes in patients treated with intravenous racemic sotalol. Acad Emerg Med 2001; 8: 117–124.
11.
Li X, Zhang Y, Liu H, Jiang H, Ge H, Zhang Y: Efficacy of intravenous sotalol for treatment of incessant tachyarrhythmias in children. Am J Cardiol 2017; 119: 1366–1370.
12.
Thomas SP, Guy D, Wallace E, Crampton R, Kijvanit P, Eipper V, Ross DL, Cooper MJ: Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial. Am Heart J 2004; 147:E3.
13.
Singh SN, Tang XC, Reda D, Singh B: Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial. Heart Rhythm 2009; 6: 152–155.
14.
Knudson JD, Cannon BC, Kim JJ, Moffett BS: High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias. Pediatr Cardiol 2011; 327: 896–903.
15.
Gomes JA, Ip J, Santoni-Rugiu F, Mehta D, Ergin A, Lansman S, Pe E, Newhouse TT, Chao S: Oral d,l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1999; 34: 334–339.
16.
Yarlagadda B, Vuddanda V, Dar T, Jazayeri MA, Parikh V, Turagam MK, Lavu M, Avula SR, Atkins D, Bommana S, Gopinathannair R, Yeruva MR, Lakkireddy D: Safety and Efficacy of Inpatient Initiation of Dofetilide versus Sotalol for atrial fibrillation. J Atr Fibrillation 2017; 10: 1805.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.